Related Experiment Videos
Bromocriptine augmentation therapy in a patient with Cotard's syndrome
Shuko Kondo1, Hiroshi Hayashi, Takuya Eguchi
1Department of Neuropsychiatry, Yamagata University School of Medicine, 990-9585, Yamagata, Japan. otani@med.id.yamagata-u.ac.jp
Summary
This study reports a case of Cotard's syndrome in a bipolar I disorder patient. Bromocriptine augmentation therapy showed significant improvement in delusions and depressive symptoms.
Area of Science:
- Neuropsychiatry
- Mood Disorders
- Psychopharmacology
Background:
- Cotard's syndrome is a rare neuropsychiatric condition characterized by delusions of negation.
- Bipolar I disorder is a mood disorder associated with significant functional impairment.
- Treatment resistance is common in severe mood disorders with psychotic features.
Observation:
- A 72-year-old female with bipolar I disorder presented with Cotard's syndrome.
- The patient exhibited severe depressive symptoms and delusions of negation.
- Standard treatments including antipsychotics, antidepressants, and lithium augmentation were ineffective.
Findings:
- Addition of bromocriptine (2.5-5 mg/day) to clomipramine and lithium resulted in dramatic improvement.
- Bromocriptine augmentation effectively reduced both depressive symptoms and nihilistic delusions.
- This suggests a potential role for dopamine agonists in managing specific psychotic features of mood disorders.
Implications:
- Bromocriptine may be a valuable therapeutic option for treatment-resistant Cotard's syndrome in bipolar disorder.
- Further research is warranted to explore the efficacy and mechanisms of bromocriptine in similar cases.
- This finding could inform treatment strategies for patients with complex mood and psychotic presentations.